Summary
Pfizer has been active since 1954 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show a net result of €3.7m. Equity remains stable across the filed financial years (±2.2% per year). Its net result ranks better than 94% of 6,087 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).
Financials · financial year 2025, full format
In the rankings
#4 employer in Elsene, Wholesale and retail trade sector#4 company by total assets in Elsene, Wholesale and retail trade sector#7 oldest company in Elsene, Wholesale and retail trade sector
Turnover
€358.3m▲ 6.5%
2024 · €336.5m
EBIT margin
4.2%▼ 6.5pp
2024 · 10.8%
Net result
€3.7m▼ 84.2%
2024 · €23.2m
Working capital
€141.2m▲ 11.9%
2024 · €126.1m
Trend over the years
2021 to 2025, 5 financial years 2018 to 2025, 8 financial years
The operating result falls in 2025; 2025 is 58% below 2024 and is the lowest result in the available series.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
Turnover€358.3m
2025
Operating result€15.1m
2025
Net result€3.7m
2025
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Total assets€377.4m
2025
Equity€90.4m
2022
Debt€226.6m
2025
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Working capital€141.2m
2025
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
EBIT margin4.2%
2025
Return on assets (ROA)1.0%
2025
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Solvency31.7%
2022
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Current ratio1.63
2025
Average staff in full-time equivalents (FTE).
Staff (FTE)297
2025
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 46, Wholesale trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Turnover€148.7m-€220.6m▲ 48.4%€240.2m▲ 8.9%€469.5m▲ 95.5%€548.2m▲ 16.8%€349.4m▼ 36.3%€336.5m▼ 3.7%€358.3m▲ 6.5%
Operating result€12.1m-€12.5m▲ 3.1%€14.7m▲ 18.3%€27.1m▲ 83.9%€29.8m▲ 10.1%€20.7m▼ 30.7%€36.2m▲ 75.2%€15.1m▼ 58.2%
Net result€8.0m-€9.4m▲ 16.7%€9.7mabove the sector's middle half▲ 2.9%€19.5mabove the sector's middle half▲ 102%€21.6mabove the sector's middle half▲ 10.7%€12.9mabove the sector's middle half▼ 40.3%€23.2mabove the sector's middle half▲ 79.7%€3.7mabove the sector's middle half▼ 84.2%
EBIT margin8.1%-5.6%▼ 2.5pp6.1%▲ 0.5pp5.8%▼ 0.4pp5.4%▼ 0.3pp5.9%▲ 0.5pp10.8%▲ 4.8pp4.2%▼ 6.5pp
Equity€89.8m-€139.7m▲ 55.6%€99.3mabove the sector's middle half▼ 28.9%€118.8mabove the sector's middle half▲ 19.7%€90.4mabove the sector's middle half▼ 23.9%
Total assets€166.9m-€283.8m▲ 70.0%€194.2mabove the sector's middle half▼ 31.6%€254.7mabove the sector's middle half▲ 31.2%€285.3mabove the sector's middle half▲ 12.0%€383.4mabove the sector's middle half▲ 34.4%€474.6mabove the sector's middle half▲ 23.8%€377.4mabove the sector's middle half▼ 20.5%
Debt€73.7m-€141.8m▲ 92.5%€92.3m▼ 34.9%€132.2m▲ 43.2%€183.5m▲ 38.8%€275.7m▲ 50.3%€346.0m▲ 25.5%€226.6m▼ 34.5%
Working capital€87.6m-€136.5m▲ 55.8%€94.0mabove the sector's middle half▼ 31.2%€114.5mabove the sector's middle half▲ 21.8%€91.4mabove the sector's middle half▼ 20.2%€123.1mabove the sector's middle half▲ 34.7%€126.1mabove the sector's middle half▲ 2.5%€141.2mabove the sector's middle half▲ 11.9%
Solvency53.8%-49.2%▼ 4.6pp51.2%within the sector's middle half▲ 1.9pp46.7%within the sector's middle half▼ 4.5pp31.7%within the sector's middle half▼ 15.0pp
Current ratio2.25-2.01▼ 0.242.05within the sector's middle half▲ 0.041.88within the sector's middle half▼ 0.171.50within the sector's middle half▼ 0.381.49within the sector's middle half▼ 0.011.37within the sector's middle half▼ 0.121.63within the sector's middle half▲ 0.26
Return on assets (ROA)4.8%-3.3%▼ 1.5pp5.0%within the sector's middle half▲ 1.7pp7.7%within the sector's middle half▲ 2.7pp7.6%within the sector's middle half▼ 0.1pp3.4%within the sector's middle half▼ 4.2pp4.9%within the sector's middle half▲ 1.5pp1.0%within the sector's middle half▼ 3.9pp
Staff (FTE)279.6-319.4▲ 14.2%330.1above the sector's middle half▲ 3.4%333.4above the sector's middle half▲ 1.0%336.3above the sector's middle half▲ 0.9%338.2above the sector's middle half▲ 0.6%323above the sector's middle half▼ 4.5%297above the sector's middle half▼ 8.0%
above
within
below
the middle half of NACE 46, Wholesale trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €377.4m
Fixed assets
€11.4m ▲ 12.9%
Current assets
€365.9m ▼ 21.2%
Key figures and ratios
EBITDA
€16.2m▼
2024 · €37.3m
Cash flow
€4.7m▼
2024 · €24.2m
Quick ratio
0.85▲
2024 · 0.82
Interest coverage
5.67▼
2024 · 8.59
Debt ≤ 1 year
€224.7m▼
2024 · €338.4m
Income taxes
€9.1m▼
2024 · €9.5m
Staff costs
€53.9m▼
2024 · €76.4m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Operating income70/76A | €222.9m | €282.6m | €317.3m | €543.0m | €632.9m | €413.6m | €392.6m | €414.1m | ▲ 5.5% |
| Turnover70 | €148.7m | €220.6m | €240.2m | €469.5m | €548.2m | €349.4m | €336.5m | €358.3m | ▲ 6.5% |
| Other operating income74 | €74.2m | €62.0m | €77.1m | €71.9m | €84.7m | €64.2m | €56.1m | €55.8m | ▼ 0.6% |
| Non-recurring operating income76A | - | - | - | €1.6m | - | - | - | - | - |
| Operating charges60/66A | €210.8m | €270.2m | €302.6m | €515.9m | €603.1m | €392.9m | €356.3m | €399.0m | ▲ 12.0% |
| Goods for resale, raw materials and consumables60 | €113.3m | €156.6m | €196.4m | €401.7m | €467.8m | €275.1m | €222.0m | €274.6m | ▲ 23.7% |
| Change in stocks: decrease (increase)609 | -€5.9m | -€21.5m | -€0.2m | €3.8m | -€40.0m | -€42.2m | -€23.7m | €17.3m | - |
| Services and other goods61 | €41.1m | €46.3m | €44.4m | €44.4m | €47.0m | €42.9m | €36.9m | €34.7m | ▼ 6.0% |
| Remuneration, social security and pensions62 | €41.1m | €48.5m | €50.9m | €56.5m | €66.1m | €64.9m | €76.4m | €53.9m | ▼ 29.4% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €1.7m | €3.0m | €1.1m | €1.2m | €1.1m | €1.0m | €1.0m | €1.0m | ▼ 3.4% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | -€0.4m | €1.2m | €3.2m | -€1.8m | -€0.3m | €2.9m | €5.8m | -€4.4m | - |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | €2.2m | -€1.2m | €0.2m | €1.1m | €7.8m | -€7.0m | -€2.3m | €18.4m | - |
| Other operating charges640/8 | €11.9m | €15.8m | €6.3m | €12.8m | €13.5m | €13.2m | €16.5m | €20.8m | ▲ 26.1% |
| Operating profit (loss)9901 | €12.1m | €12.5m | €14.7m | €27.1m | €29.8m | €20.7m | €36.2m | €15.1m | ▼ 58.2% |
| Recurring financial income75 | €0.4m | €0.6m | €0.2m | €0.2m | €0.8m | €1.2m | €1.3m | €1.3m | ▼ 1.7% |
| Income from current assets751 | - | - | €0.01m | €0.01m | €0.1m | €0.7m | €1.1m | €0.7m | ▼ 31.0% |
| Other financial income752/9 | €0.4m | €0.6m | €0.2m | €0.2m | €0.7m | €0.4m | €0.3m | €0.6m | ▲ 124% |
| Financial charges65/66B | €0.5m | €0.8m | €0.3m | €0.3m | €1.0m | €3.8m | €4.9m | €3.7m | ▼ 25.4% |
| Recurring financial charges65 | €0.5m | €0.8m | €0.3m | €0.3m | €1.0m | €3.8m | €4.9m | €3.7m | ▼ 25.4% |
| Debt charges650 | - | - | €306 | €0.1m | €0.3m | €3.3m | €4.3m | €2.8m | ▼ 34.3% |
| Other financial charges652/9 | €0.5m | €0.8m | €0.3m | €0.2m | €0.7m | €0.5m | €0.6m | €0.8m | ▲ 43.5% |
| Profit (loss) for the period before taxes9903 | €11.9m | €12.3m | €14.6m | €27.0m | €29.6m | €18.0m | €32.6m | €12.8m | ▼ 60.8% |
| Income taxes67/77 | €3.9m | €3.0m | €5.0m | €7.5m | €8.0m | €5.1m | €9.5m | €9.1m | ▼ 3.5% |
| Taxes670/3 | €4.0m | €3.0m | €5.0m | €7.5m | €8.1m | €5.1m | €9.5m | €9.1m | ▼ 3.5% |
| Tax adjustments and reversals of tax provisions77 | €0.06m | - | €0.001m | €0.009m | €0.1m | - | - | - | - |
| Profit (loss) for the period9904 | €8.0m | €9.4m | €9.7m | €19.5m | €21.6m | €12.9m | €23.2m | €3.7m | ▼ 84.2% |
| Profit (loss) for the period to be appropriated9905 | €8.0m | €9.4m | €9.7m | €19.5m | €21.6m | €12.9m | €23.2m | €3.7m | ▼ 84.2% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €166.9m | €283.8m | €194.2m | €254.7m | €285.3m | €383.4m | €474.6m | €377.4m | ▼ 20.5% |
| Fixed assets21/28 | €9.0m | €12.0m | €10.9m | €10.1m | €11.2m | €11.1m | €10.1m | €11.4m | ▲ 12.9% |
| Intangible fixed assets21 | €0.6m | - | - | - | - | - | - | - | - |
| Tangible fixed assets22/27 | €7.8m | €6.9m | €6.1m | €5.3m | €6.4m | €6.0m | €5.1m | €6.4m | ▲ 25.5% |
| Plant, machinery and equipment23 | €1.1m | €0.9m | €0.8m | €0.8m | €0.7m | €0.7m | €0.5m | €0.4m | ▼ 23.4% |
| Furniture and vehicles24 | €0.9m | €0.7m | €0.5m | €0.3m | €0.6m | €0.6m | €0.9m | €0.7m | ▼ 24.8% |
| Other tangible fixed assets26 | €5.8m | €5.2m | €4.7m | €4.1m | €4.3m | €4.1m | €3.5m | €3.0m | ▼ 15.6% |
| Assets under construction and advance payments27 | €0.006m | €0.2m | €0.1m | €0.08m | €0.8m | €0.6m | €0.09m | €2.3m | ▲ 26× |
| Financial fixed assets28 | €0.5m | €5.1m | €4.8m | €4.8m | €4.8m | €5.1m | €5.1m | €5.1m | ▲ 0.3% |
| Affiliated companies280/1 | €26 | €4.2m | €4.2m | €4.2m | €4.2m | €4.2m | €4.2m | €4.2m | = |
| Participating interests280 | €26 | €4.2m | €4.2m | €4.2m | €4.2m | €4.2m | €4.2m | €4.2m | = |
| Other financial fixed assets284/8 | €0.5m | €0.9m | €0.6m | €0.5m | €0.6m | €0.8m | €0.8m | €0.8m | ▲ 1.8% |
| Amounts receivable and cash guarantees285/8 | €0.5m | €0.9m | €0.6m | €0.5m | €0.6m | €0.8m | €0.8m | €0.8m | ▲ 1.8% |
| Current assets29/58 | €158.0m | €271.7m | €183.2m | €244.6m | €274.0m | €372.3m | €464.5m | €365.9m | ▼ 21.2% |
| Stocks and contracts in progress3 | €60.0m | €95.4m | €92.5m | €90.4m | €130.7m | €170.1m | €188.0m | €175.1m | ▼ 6.9% |
| Stocks30/36 | €60.0m | €95.4m | €92.5m | €90.4m | €130.7m | €170.1m | €188.0m | €175.1m | ▼ 6.9% |
| Goods purchased for resale34 | €60.0m | €95.4m | €92.5m | €90.4m | €130.7m | €170.1m | €188.0m | €175.1m | ▼ 6.9% |
| Amounts receivable within one year40/41 | €75.2m | €83.0m | €79.9m | €111.3m | €142.4m | €179.8m | €165.6m | €166.0m | ▲ 0.2% |
| Trade receivables40 | €73.1m | €80.9m | €74.2m | €109.6m | €136.3m | €171.0m | €161.0m | €123.7m | ▼ 23.2% |
| Other amounts receivable41 | €2.1m | €2.1m | €5.8m | €1.7m | €6.1m | €8.8m | €4.6m | €42.3m | ▲ 823% |
| Current investments50/53 | - | - | €381 | - | - | €0.06m | €87.1m | €0.02m | ▼ 100.0% |
| Other investments51/53 | - | - | €381 | - | - | €0.06m | €87.1m | €0.02m | ▼ 100.0% |
| Cash at bank and in hand54/58 | €21.2m | €90.5m | €8.8m | €40.7m | €0.7m | €21.9m | €21.3m | €23.9m | ▲ 12.1% |
| Deferred charges and accrued income490/1 | €1.5m | €2.9m | €2.0m | €2.2m | €0.2m | €0.4m | €2.5m | €0.9m | ▼ 63.8% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €166.9m | €283.8m | €194.2m | €254.7m | €285.3m | €383.4m | €474.6m | €377.4m | ▼ 20.5% |
| Equity10/15 | €89.8m | €139.7m | €99.3m | €118.8m | €90.4m | - | - | - | - |
| Contributions10/11 | €28.9m | €39.7m | €40.8m | €40.8m | €40.8m | €40.8m | €40.8m | €40.8m | = |
| Capital10 | €28.9m | €39.7m | €39.7m | €39.7m | €39.7m | €39.7m | €39.7m | €39.7m | = |
| Issued capital100 | €28.9m | €39.7m | €39.7m | €39.7m | €39.7m | €39.7m | €39.7m | €39.7m | = |
| Contributions outside capital11 | €0.8m | €1.1m | €1.1m | €1.1m | €1.1m | €1.1m | €1.1m | €1.1m | = |
| Share premium1100/10 | - | - | - | €1.1m | €1.1m | €1.1m | €1.1m | €1.1m | = |
| Reserves13 | €5.9m | €8.0m | €8.0m | €8.0m | €8.0m | €8.0m | €8.0m | €8.0m | = |
| Non-distributable reserves130/1 | - | - | €4.0m | €4.0m | €4.0m | €4.0m | €4.0m | €4.0m | = |
| Legal reserve130 | €2.9m | €4.0m | €4.0m | €4.0m | €4.0m | €4.0m | €4.0m | €4.0m | = |
| Reserves not available under the articles1311 | €0.02m | €0.02m | - | - | - | - | - | - | - |
| Other1319 | - | - | €0.02m | €0.02m | €0.02m | €0.02m | €0.02m | €0.02m | = |
| Tax-exempt reserves132 | €2.9m | €4.0m | €4.0m | €4.0m | €4.0m | €4.0m | €4.0m | €4.0m | = |
| Distributable reserves133 | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | = |
| Profit (loss) carried forward14 | €54.2m | €90.8m | €50.5m | €70.0m | €41.6m | €54.5m | €77.7m | €81.4m | ▲ 4.7% |
| Provisions and deferred taxes16 | €3.5m | €2.3m | €2.5m | €3.6m | €11.4m | - | - | - | - |
| Provisions for liabilities and charges160/5 | €3.5m | €2.3m | €2.5m | €3.6m | €11.4m | €4.4m | €2.1m | €20.5m | ▲ 876% |
| Pensions and similar obligations160 | - | - | - | - | €3.7m | - | - | - | - |
| Other liabilities and charges164/5 | €3.5m | €2.3m | €2.5m | €3.6m | €7.6m | €4.4m | €2.1m | €20.5m | ▲ 876% |
| Amounts payable17/49 | €73.7m | €141.8m | €92.3m | €132.2m | €183.5m | €275.7m | €346.0m | €226.6m | ▼ 34.5% |
| Amounts payable within one year42/48 | €70.3m | €135.2m | €89.2m | €130.1m | €182.6m | €249.2m | €338.4m | €224.7m | ▼ 33.6% |
| Financial debts43 | - | - | - | - | €81.3m | €146.6m | €0.02m | €162.9m | ▲ 6,663× |
| Credit institutions430/8 | - | - | - | - | - | - | €0.02m | €0.8m | ▲ 34× |
| Other loans439 | - | - | - | - | €81.3m | €146.6m | - | €162.0m | - |
| Trade debts44 | €18.4m | €63.3m | €27.3m | €66.4m | €26.4m | €5.9m | €75.9m | €34.0m | ▼ 55.1% |
| Suppliers440/4 | €18.4m | €63.3m | €27.3m | €66.4m | €26.4m | €5.9m | €75.9m | €34.0m | ▼ 55.1% |
| Taxes, remuneration and social security45 | €52.0m | €71.9m | €61.9m | €63.7m | €75.0m | €76.4m | €255.6m | €23.3m | ▼ 90.9% |
| Taxes450/3 | €40.8m | €58.8m | €49.1m | €46.9m | €52.4m | €60.9m | €237.6m | €7.0m | ▼ 97.1% |
| Remuneration and social security454/9 | €11.2m | €13.2m | €12.8m | €16.8m | €22.5m | €15.6m | €18.0m | €16.3m | ▼ 9.3% |
| Other amounts payable47/48 | - | - | - | €0.02m | - | €20.3m | €6.9m | €4.5m | ▼ 35.0% |
| Accrued charges and deferred income492/3 | €3.4m | €6.6m | €3.1m | €2.1m | €0.8m | €26.5m | €7.7m | €1.9m | ▼ 74.7% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €8.0m | €9.4m | €9.7m | €19.5m | €21.6m | €12.9m | €23.2m | €3.7m | ▼ 84.2% |
| + Depreciation and write-downs630 | €1.7m | €3.0m | €1.1m | €1.2m | €1.1m | €1.0m | €1.0m | €1.0m | ▼ 3.4% |
| Operating cash flow (approximation) | €9.7m | €12.3m | €10.8m | €20.7m | €22.7m | €13.9m | €24.2m | €4.7m | ▼ 80.7% |
| Investment in fixed assets (approximation) | - | -€6.0m | -€0.05m | -€0.3m | -€2.3m | -€0.8m | -€0.09m | -€2.3m | ▼ 2,470% |
| Change in cash | - | €69.3m | -€81.7m | €31.9m | -€40.0m | €21.2m | -€0.6m | €2.6m | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Latest 10 of 50 filings with the National Bank
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 30-11-2025 | full format | 02-06-2026 | 2026-00137670 |
| 30-11-2024 | full format | 23-05-2025 | 2025-00110685 |
| 30-11-2023 | full format | 21-05-2024 | 2024-00094385 |
| 30-11-2022 | full format | 23-05-2023 | 2023-00098666 |
| 30-11-2021 | full format | 01-06-2022 | 2022-20046669 |
| 30-11-2020 | full format | 31-05-2021 | 2021-16800407 |
| 30-11-2019 | full format | 29-06-2020 | 2020-22200444 |
| 30-11-2018 | full format | 22-05-2019 | 2019-14500482 |
| 30-11-2017 | full format | 30-05-2018 | 2018-15300114 |
| 30-11-2016 | full format | 09-06-2017 | 2017-16800333 |
Similar companies · same sector, comparable size
SIEMENS HEALTHCARE
BE 0453.139.656
Dilbeek · FTE 294.4
Terumo BCT Europe
BE 0413.166.055
Zaventem · FTE 271
JOHNSON & JOHNSON MEDICAL
BE 0425.967.580
Machelen (Brab.) · FTE 267.5
Medtronic Belgium
BE 0415.262.839
Jette · FTE 255.7
CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE
BE 0403.057.962
Anderlecht · FTE 243.9
Of the 1,866 active companies whose main activity is wholesale of pharmaceutical and medical goods (NACE 46460), figures are known for 1,130. 180 are within a factor 10 of this headcount. These 5 are the closest to it. See the whole sector
Subsidies and aid
European research
1 projectProgrammes
Projects
FORTIFY - FRAMEWORK FOR OPTIMIZED REGULATION, TRADE SECRETS, AND INTELLECTUAL PROPERTY IN A FEDERATED EUROPEAN HEALTH DATA SPACE
Public contracts
54 awards · 2024 to 2026
Antimycotica: Voriconazole IV
Antimycotica: Anidulafungine IV
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Azithromycine PO siroop
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Clindamycine PO
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Fluconazol PO caps
Show 45 more contracts
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Voriconazol IV
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Anidulafungine IV
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Azithromycine PO siroop
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Clindamycine PO
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Fluconazol PO caps
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Voriconazol IV
RAAMOVEREENKOMST VOOR HET LEVEREN VAN ANTIBIOTICA, ANTIMYCOTICA EN ANTIPARASITAIRE MIDDELEN: Raamovereenkomst voor het leveren van Anidulafungine IV
Spécialités pharmaceutiques à base de fluconazole, voriconazole, anidulafungine, posaconazole et caspofungine: Spécialités pharmaceutiques à base de voriconazole (voie intraveineuse)
Spécialités pharmaceutiques à base de fluconazole, voriconazole, anidulafungine, posaconazole et caspofungine: Spécialités pharmaceutiques à base d'anidulafungine
Spécialités pharmaceutiques à base de fluconazole, voriconazole, anidulafungine, posaconazole et caspofungine: Spécialités pharmaceutiques à base de fluconazole (voie orale, comprimés)
Leveren van orale antibiotica: Azithromycine voor oraal gebruik
Leveren van orale antibiotica: Clindamycine voor oraal gebruik
Leveren van orale antibiotica: Linezolid voor oraal gebruik - tablet
Raamovereenkomst voor de levering van antimycotica: Anidulafungine IV
Raamovereenkomst voor de levering van antimycotica: Voriconazol PO siroop
Raamovereenkomst voor de levering van antimycotica: Voriconazol IV
Leveren van Trastuzumab en Rituximab voor intraveneus gebruik: Leveren van Trastuzumab 150 mg voor intraveneus gebruik
Bévacizumab
Diverse geneesmiddelen oncologie PO voor Helixziekenhuizen: Bosutinib
Diverse geneesmiddelen oncologie PO voor Helixziekenhuizen: Bosutinib
Accord-cadre relatif à la fourniture d’antibiotiques - antifongiques pour les besoins des pharmacies de Vivalia: CLINDAMYCINE : Gélules
Accord-cadre relatif à la fourniture d’antibiotiques - antifongiques pour les besoins des pharmacies de Vivalia: LINEZOLIDE : Solution
Accord-cadre relatif à la fourniture d’antibiotiques - antifongiques pour les besoins des pharmacies de Vivalia: VORICONAZOL : Comprimés
Leveren van antibiotica, antivirale middelen en antimycotica: Clindamycine - ATC J01FF01 - PO
Leveren van antibiotica, antivirale middelen en antimycotica: Clindamycine - ATC J01FF01 - IV
Leveren van antibiotica, antivirale middelen en antimycotica: Linezolid - ATC J01XX08 - PO
Leveren van antibiotica, antivirale middelen en antimycotica: Anidulafungine - ATC J02AX06 - IV
Leveren van antibiotica, antivirale middelen en antimycotica: Voriconazole - ATC J02AC03 - PO
Leveren van antibiotica, antivirale middelen en antimycotica: Voriconazole - ATC J02AC03 - IV
Leveren van antibiotica, antivirale middelen en antimycotica: Clindamycine - ATC J01FF01 - PO
Leveren van antibiotica, antivirale middelen en antimycotica: Clindamycine - ATC J01FF01 - IV
Leveren van antibiotica, antivirale middelen en antimycotica: Linezolid - ATC J01XX08 - PO
Leveren van antibiotica, antivirale middelen en antimycotica: Anidulafungine - ATC J02AX06 - IV
Leveren van antibiotica, antivirale middelen en antimycotica: Voriconazole - ATC J02AC03 - PO
Leveren van antibiotica, antivirale middelen en antimycotica: Voriconazole - ATC J02AC03 - IV
Raamovereenkomst voor het aankopen en leveren van Trastuzumab en Rituximab: Trastuzumab IV
Accord-cadre ayant pour objet la fourniture d'antibactériens par voie injectable: Tigécycline 50 mg, IV
Anti-infectieux à usage systémique: Tigécycline injectable
Anti-infectieux à usage systémique: Voriconazole injectable
Anti-infectieux à usage systémique: Anidulafungine injectable
Raamovereenkomst voor de aankoop en het leveren van anti-infectieuze geneesmiddelen: Linezolid inj
Raamovereenkomst voor de aankoop en het leveren van anti-infectieuze geneesmiddelen: Voriconazole inj
Raamovereenkomst voor de aankoop en het leveren van anti-infectieuze geneesmiddelen: Anidulafungin
Raamovereenkomst voor de aankoop en het leveren van anti-infectieuze geneesmiddelen: Azithromycine PO
Raamovereenkomst voor de aankoop en het leveren van anti-infectieuze geneesmiddelen: Clindamycine PO
The 50 most recent of 54 awards.
Source: TED (Tenders Electronic Daily), Publications Office of the European Union. Values as the buyer published them; for a framework agreement, a ceiling.